AG1433

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562976

CAS#: 168836-03-1

Description: AG1433 is an inhibitor of tyrosine kinases. It also acts as a direct and selective inhibitor of photosynthetic PEP carboxylase and an inhibitor of PDGFR-β, Flk-1, and angiogenesis.


Chemical Structure

img
AG1433
CAS# 168836-03-1

Theoretical Analysis

MedKoo Cat#: 562976
Name: AG1433
CAS#: 168836-03-1
Chemical Formula: C16H14N2O2
Exact Mass: 266.11
Molecular Weight: 266.300
Elemental Analysis: C, 72.17; H, 5.30; N, 10.52; O, 12.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AG1433; AG-1433; AG 1433; Tyrphostin AG-1433; Tyrphostin AG 1433; Tyrphostin AG1433;

IUPAC/Chemical Name: 2-(3,4-dihydroxyphenyl)-6,7-dimethylquinoxaline

InChi Key: SMKFYHOKXJUJOT-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14N2O2/c1-9-5-12-13(6-10(9)2)18-14(8-17-12)11-3-4-15(19)16(20)7-11/h3-8,19-20H,1-2H3

SMILES Code: CC1=C(C)C=C2N=CC(C3=CC=C(O)C(O)=C3)=NC2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 266.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Serban F, Daianu O, Tataranu LG, Artene SA, Emami G, Georgescu AM, Alexandru O, Purcaru SO, Tache DE, Danciulescu MM, Sfredel V, Dricu A. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma. J Immunoassay Immunochem. 2017;38(1):21-33. doi: 10.1080/15321819.2016.1209217. Epub 2016 Jul 5. PubMed PMID: 27379831.

2: Popescu AM, Alexandru O, Brindusa C, Purcaru SO, Tache DE, Tataranu LG, Taisescu C, Dricu A. Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Int J Clin Exp Pathol. 2015 Jul 1;8(7):7825-37. eCollection 2015. PubMed PMID: 26339347; PubMed Central PMCID: PMC4555675.

3: Kim TS, Kawaguchi M, Suzuki M, Jung CG, Asai K, Shibamoto Y, Lavin MF, Khanna KK, Miura Y. The ZFHX3 (ATBF1) transcription factor induces PDGFRB, which activates ATM in the cytoplasm to protect cerebellar neurons from oxidative stress. Dis Model Mech. 2010 Nov-Dec;3(11-12):752-62. doi: 10.1242/dmm.004689. Epub 2010 Sep 27. PubMed PMID: 20876357.

4: Akiyama N, Naruse K, Kobayashi Y, Nakamura N, Hamada Y, Nakashima E, Matsubara T, Oiso Y, Nakamura J. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-beta increases migration of aortic smooth muscle cells. J Mol Cell Cardiol. 2008 Aug;45(2):326-32. doi: 10.1016/j.yjmcc.2008.04.006. Epub 2008 Apr 25. PubMed PMID: 18561944.

5: Chen K, Albano A, Ho A, Keaney JF Jr. Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation. J Biol Chem. 2003 Oct 10;278(41):39527-33. Epub 2003 Jul 30. PubMed PMID: 12890678.